(Q38022265)

English

Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.

scientific article published on 28 June 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22741814%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22741814%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Huntington's disease

0 references

Alzheimer's disease

0 references

amyotrophic lateral sclerosis

0 references

neurodegeneration

1 reference

based on heuristic

inferred from title

Parkinson's disease

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22741814%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Christina L.L. Chai

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22741814%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22741814%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

author name string

Beáta Sperlágh

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22741814%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Paul B Huleatt

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22741814%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

language of work or name

0 references

publication date

28 June 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22741814%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Expert Opinion on Investigational Drugs

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22741814%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22741814%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22741814%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1267-1308

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22741814%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

An update on pharmacological approaches to neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

List of drugs in development for neurodegenerative diseases. Update September 2005.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

The future of Alzheimer's disease: the next 10 years

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Alzheimer's disease: strategies for disease modification

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

SK-PC-B70M alleviates neurologic symptoms in G93A-SOD1 amyotrophic lateral sclerosis mice.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Dimebon inhibits calcium-induced swelling of rat brain mitochondria but does not alter calcium retention or cytochrome C release

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

The cholinergic system in aging and neuronal degeneration

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

RG3487, a novel nicotinic α7 receptor partial agonist, improves cognition and sensorimotor gating in rodents.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Novel γ-secretase modulators: a review of patents from 2008 to 2010.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

The amyloid hypothesis for Alzheimer's disease: a critical reappraisal

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Notch signaling, gamma-secretase inhibitors, and cancer therapy

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

ST101 induces a novel 17 kDa APP cleavage that precludes Aβ generation in vivo

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Alzheimer's disease & metals: therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

The Alzheimer's therapeutic PBT2 promotes amyloid-β degradation and GSK3 phosphorylation via a metal chaperone activity

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Properties of scyllo-inositol as a therapeutic treatment of AD-like pathology

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Sodium/myo-Inositol transporters: substrate transport requirements and regional brain expression in the TgCRND8 mouse model of amyloid pathology

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Are Anti-Angiogenic Drugs Useful in Neurodegenerative Disorders?

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Non-steroidal anti-inflammatory drugs stimulate secretion of non-amyloidogenic precursor protein

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Thalidomide inhibition of perturbed vasculature and glial-derived tumor necrosis factor-alpha in an animal model of inflamed Alzheimer's disease brain

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Restraining tumor necrosis factor-alpha by thalidomide prevents the amyloid beta-induced impairment of recognition memory in mice

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

T-817MA, a neuroprotective agent, attenuates the motor and cognitive impairments associated with neuronal degeneration in P301L tau transgenic mice.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

The histamine H3 receptor: an attractive target for the treatment of cognitive disorders

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Discovery of Histamine H3 Antagonists for the Treatment of Cognitive Disorders and Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Several down, a few to go: histamine H3 receptor ligands making the final push towards the market?

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

PDE inhibitors in psychiatry--future options for dementia, depression and schizophrenia?

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Inhibition of phosphodiesterase-4 reverses memory deficits produced by Aβ25-35 or Aβ1-40 peptide in rats

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Treating brain tumors with PDE4 inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Etazolate improves performance in a foraging and homing task in aged rats

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

α-secretase in Alzheimer's disease: molecular identity, regulation and therapeutic potential

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

EHT0202 in Alzheimer's disease: a 3-month, randomized, placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Protection against inflammatory neurodegeneration and glial cell death by 7beta-hydroxy epiandrosterone, a novel neurosteroid

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

The neuroprotective mechanism of action of the multimodal drug ladostigil

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

NAP (davunetide) provides functional and structural neuroprotection

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

"Lest we forget you--methylene blue...".

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

ACS chemical neuroscience molecule spotlight on ELND006: another γ-secretase inhibitor fails in the clinic

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

γ-Secretase modulators as potential disease modifying anti-Alzheimer's drugs

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

CHF5074, a novel gamma-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

The γ-secretase modulator CHF5074 reduces the accumulation of native hyperphosphorylated tau in a transgenic mouse model of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Developing β-secretase inhibitors for treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study).

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Heparin/heparan sulphate-based drugs

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Structural determinants of the multifunctional profile of dual binding site acetylcholinesterase inhibitors as anti-Alzheimer agents.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

The GSK3 hypothesis of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Oral administration of a GSK3 inhibitor increases brain insulin-like growth factor I levels

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Relationship between late-life hypertension, blood pressure, and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

5-HT4 receptor and Alzheimer's disease: the amyloid connection

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

5-HT(4) receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Inhibitors for human glutaminyl cyclase by structure based design and bioisosteric replacement.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Aβ is induced by pyroglutamate-Aβ formation.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

The pharmacology of sigma-1 receptors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

The sigma-1 receptor chaperone as an inter-organelle signaling modulator

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Neuroprotective effects of sigma-1 receptor agonists against beta-amyloid-induced toxicity.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Heat shock protein 90: translation from cancer to Alzheimer's disease treatment?

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Discovery and development of heat shock protein 90 inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

HDAC inhibitors and neurodegeneration: at the edge between protection and damage

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Multiple roles of HDAC inhibition in neurodegenerative conditions.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Memory enhancement: the search for mechanism-based drugs

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Ampakines cause sustained increases in brain-derived neurotrophic factor signaling at excitatory synapses without changes in AMPA receptor subunit expression

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Priorities in Parkinson's disease research

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Adenosine, adenosine A 2A antagonists, and Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Istradefylline for the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Recent developments in adenosine receptor ligands and their potential as novel drugs

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Characterization of the Potent and Highly Selective A(2A) Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyraz olo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

An in vivo pharmacological evaluation of pardoprunox (SLV308)--a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY-5Y cells

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Safinamide: from molecular targets to a new anti-Parkinson drug

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

An open-label, positron emission tomography study to assess adenosine A2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Role of glial cell derived neurotrophic factor in the protective effect of smilagenin on rat mesencephalic dopaminergic neurons damaged by MPP+.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Regulation of M1-receptor mRNA stability by smilagenin and its significance in improving memory of aged rats

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Mice lacking major brain gangliosides develop parkinsonism

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Pharmacological therapy in Parkinson's disease: focus on neuroprotection

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Altered tryptophan metabolism in Parkinson's disease: a possible novel therapeutic approach.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

The preclinical discovery of amyotrophic lateral sclerosis drugs

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Emerging drugs for amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Olesoxime (TRO19622): A Novel Mitochondrial-Targeted Neuroprotective Compound

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Review: The role of mitochondria in the pathogenesis of amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Manganese porphyrin given at symptom onset markedly extends survival of ALS mice

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Design of Mn porphyrins for treating oxidative stress injuries and their redox-based regulation of cellular transcriptional activities

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Neuroprotection for Huntington's disease: ready, set, slow

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Huntington's disease: progress and potential in the field

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Ethyl-EPA in Huntington disease: potentially relevant mechanism of action

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death).

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Sirtuins inhibitors: the approach to affinity and selectivity

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Sirtuins--novel therapeutic targets to treat age-associated diseases

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Natural products as a source of Alzheimer's drug leads

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Bringing natural products into the fold - exploring the therapeutic lead potential of secondary metabolites for the treatment of protein-misfolding-related neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Pharma-nutrition interface: the gap is narrowing

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

The emergence of designed multiple ligands for neurodegenerative disorders

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Designing multiple ligands - medicinal chemistry strategies and challenges

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

A robustness-based approach to systems-oriented drug design.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Multi-target-directed ligands to combat neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

From dual binding site acetylcholinesterase inhibitors to multi-target-directed ligands (MTDLs): a step forward in the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

A step further towards multitarget drugs for Alzheimer and neuronal vascular diseases: targeting the cholinergic system, amyloid-β aggregation and Ca(2+) dyshomeostasis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Multi-target-directed ligands in Alzheimer's disease treatment

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Hybrid-based multi-target ligands for the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Memoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

M30, a brain permeable multitarget neurorestorative drug in post nigrostriatal dopamine neuron lesion of parkinsonism animal models

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703178

21 January 2018

Identifiers

10.1517/13543784.2012.703178

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22741814%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22741814%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38022265&oldid=1511473912"